Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Inlyta Shows Greater Efficacy In Subpopulation; Will It Be Enough For ODAC And FDA?

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's Inlyta (axitinib), proposed to treat patients with advanced renal cell carcinoma, seems to work best with patients who have undergone cytokine treatment.

You may also be interested in...

Xalkori And Inlyta: NICE Pans Two Pfizer Oncology Drugs In Two Days

Britain’s NICE has rejected Pfizer’s Xalkori (crizotinib) for lung cancer and Inlyta (axitinib) for kidney carcinoma within two days of each other, putting drug discounts back in the spotlight.

Pfizer Inlyta’s Toxicity Data Help Clinch Unanimous ODAC Support

Axitinib as treatment for advanced renal cell carcinoma has a different toxicity profile from Bayer HealthCare's Nexavar (sorafenib), which member of the Oncologic Drugs Advisory Committee found important, even as FDA urged the panel not to focus on compartive safety and effecacy.

Axitinib Poised To Join Pfizer's RCC Drug Portfolio In 2012

Pfizer's second generation VEGF inhibitor axitinib for advanced renal cell carcinoma has been granted a standard, 10-month review by FDA.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts